Evoke Pharma Inc (EVOK)
4.41
-0.09
(-2.00%)
USD |
NASDAQ |
Nov 22, 14:53
Evoke Pharma Debt to Equity Ratio: 1.140 for Sept. 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2024 | 1.140 |
| June 30, 2024 | 1.876 |
| March 31, 2024 | 1.430 |
| December 31, 2023 | -1.938 |
| September 30, 2023 | -5.722 |
| June 30, 2023 | 9.287 |
| March 31, 2023 | 2.352 |
| December 31, 2022 | 1.224 |
| Date | Value |
|---|---|
| September 30, 2022 | 0.9037 |
| June 30, 2022 | 0.6953 |
| March 31, 2022 | 2.585 |
| December 31, 2021 | 1.406 |
| September 30, 2021 | 1.048 |
| June 30, 2021 | 0.8381 |
| March 31, 2021 | 0.6401 |
| December 31, 2020 | -1.588 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-5.722
Minimum
Sep 2023
9.287
Maximum
Jun 2023
1.011
Average
1.094
Median
Debt to Equity Ratio Benchmarks
| Repligen Corp | 0.2586 |
| Eli Lilly and Co | 2.185 |
| MEI Pharma Inc | -- |
| Revance Therapeutics Inc | -2.645 |
| NovaBay Pharmaceuticals Inc | 0.0476 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 14.15M |
| Total Liabilities (Quarterly) | 9.766M |
| Shareholders Equity (Quarterly) | 4.387M |
| Current Ratio | 1.437 |